Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...